@article{57c86b1d8b874d8a84b8e80396b3669c,
title = "ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers",
abstract = "Context and objective: To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions: Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.",
keywords = "Bladder cancer, Detection, Diagnosis, Markers, Recommendations, Screening",
author = "Kamat, {Ashish M.} and Hegarty, {Paul K.} and Gee, {Jason R.} and Clark, {Peter E.} and Svatek, {Robert S.} and Nicholas Hegarty and Shariat, {Shahrokh F.} and Evanguelos Xylinas and Schmitz-Dr{\"a}ger, {Bernd J.} and Yair Lotan and Jenkins, {Lawrence C.} and Michael Droller and {Van Rhijn}, {Bas W.} and Karakiewicz, {Pierre I.}",
note = "Funding Information: Cystoscopy alone is the most cost-effective method to detect the recurrence of bladder cancer. WLC is the gold standard for evaluation of the lower urinary tract; however, technology such as fluorescence-aided cystoscopy and NBI can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. summarizes the recommendations on screening, imaging, cystoscopy, and transurethral resection technique. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The advent of high-throughput technologies is allowing comprehensive identification of molecular targets and molecular markers specific for bladder cancer. Such identification processes may provide a better understanding of the biology associated with oncogenesis and tumor progression. However, to date, the utility of molecular markers in bladder cancer clinical decision making remains limited. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into improved clinical management of bladder cancer patients. Although this is not reality today, we envision an increasing reliance on molecularly driven collaborative approaches to cancer diagnostic and therapeutic development in the next decade. Eventually, physicians and researchers will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer. Table 5 Author contributions: Ashish M. Kamat had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Kamat. Acquisition of data: Kamat, P.K. Hegarty, Gee, Clark, Svatek, N. Hegarty, Shariat, Xylinas, Schmitz-Dr{\"a}ger, Lotan, Droller, van Rhijn, Karakiewicz. Analysis and interpretation of data: Kamat, P.K. Hegarty, Gee, Clark, Svatek, N. Hegarty, Shariat, Xylinas, Schmitz-Dr{\"a}ger, Lotan, Droller, van Rhijn, Karakiewicz. Drafting of the manuscript: Kamat, P.K. Hegarty, Gee, Clark, Svatek, N. Hegarty, Shariat, Xylinas, Schmitz-Dr{\"a}ger, Lotan, Droller, van Rhijn, Karakiewicz. Critical revision of the manuscript for important intellectual content: Kamat, P.K. Hegarty, Gee, Clark, Svatek, N. Hegarty, Shariat, Xylinas, Schmitz-Dr{\"a}ger, Lotan, Droller, van Rhijn, Karakiewicz. Statistical analysis: None. Obtaining funding: None. Administrative, technical, or material support: None. Supervision: Kamat. Other (specify): None. Financial disclosures: Ashish M. Kamat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Ashish M. Kamat has an affiliation with Archimedes, Photocure, Endo Pharmaceuticals, Sanofi Pasteur, Taris Biomedical, Alere, Cubist, FKD, and Allergan. The other authors have nothing to disclose. Funding/Support and role of the sponsor: None. Acknowledgment statement: The authors acknowledge these members of the Screening and Diagnosis Committee: Ashish M. Kamat, Paul K. Hegarty, Jason R. Gee, Peter E Clark, Robert S. Svatek, Nicholas Hegarty, Sudhir Rawal, Judson D. Davies, Sam S. Chang, Murugesan Manoharan, Amit Patel, Tim S. O{\textquoteright}Brien, Jinhai Fan, Mohan Arianayagam, William Turner, Peter Black, and Rafael Sanchez-Salas, and the members of the Molecular Markers Committee: Shahrokh F. Shariat, Evanguelos Xylinas, Bernd J. Schmitz-Dr{\"a}ger, Yair Lotan, Michael Droller, Bas W. van Rhijn, Pierre I. Karakiewicz, M{\textquoteright}Liss Hudson, Vinata B. Lokeshwar, Michael J. Marberger, George P. Hemstreet, Per-Uno Malmstrom, Osamu Ogawa, Yves Fradet, Christian Seitz, and Maxine Sun. ",
year = "2013",
month = jan,
doi = "10.1016/j.eururo.2012.09.057",
language = "English (US)",
volume = "63",
pages = "4--15",
journal = "European urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",
}